Member Info for OAPK20

Should hear from the CEO now he’s got a placing to pump.

What happened to FJB ? Need to work harder at keeping shareholders informed.

“ Company has successfully completed an antibody development programme with ProteoGenix, a France-based antibody development and production contract research organisation (CRO), with a track record in generating antibodies from development to production for therapeutic, diagnostic and research use. ”

Allan Syms, Executive Chairman of Cizzle, commented:

"We are pleased with the continued support from investors for the Placing. The net proceeds will enable the Company to enter into the manufacturing and scale up of key antibodies and reagents, that following performance testing in clinical trials are intended to become the core components of our first proposed commercial test for the CIZ1B biomarker. I look forward to providing further updates as matters progress."

Background to and reasons for the Placing

Since the release of the Company's interim results to 30 June 2023 on 28 September 2023, Cizzle has continued to make progress in the development of the Company's proprietary assay for the CIZ1B biomarker, which is highly associated with early-stage lung cancer. In particular, the Company has successfully completed an antibody development programme with ProteoGenix, a France-based antibody development and production contract research organisation (CRO), with a track record in generating antibodies from development to production for therapeutic, diagnostic and research use. The Directors believe that the new antibodies from this development programme should extend the range and proprietary rights that the Company has for detecting the CIZ1B Biomarker.

The net proceeds of the Placing will be deployed primarily to enter the scale-up and manufacturing phase for the main components of the Company's proposed commercial test for CIZ1B. Key anticipated milestones will be the production of a final antibody to accredited quality standards, other design and testing work, IP protection and progressing regulatory matters. It is currently anticipated that clinical trials of commercial grade components and ultimately the launch of the first test for CIZ1B will be in the USA. The Company will also use the net proceeds of the Placing to continue to support core research being undertaken on the Company's behalf at the University of York and for general corporate purposes.

Highlights

· Placing to raise gross proceeds of approximately £0.62 million through the issue of 31,050,000 Ordinary Shares at 2p per Ordinary Share

· The net proceeds of the Placing will be utilised towards completing the Company's first proposed commercial test to detect CIZ1B, further protect the Company's Intellectual Property (IP), progress the Company's research with the University of York and for general corporate purposes

· Upon completion of the Placing, the Company intends to terminate the £500,000 loan facility agreement with E3 Fund SP entered into on 20 September 2022. This facility has not been drawn down

If Neilin is correct and it is “Priority” then there should be an update imminently regarding the patent. 12months from submission have now passed.

A “Utility” application made in March 2023 has an average pendency of 25 months,

Application data

Application type

Utility

Examiner

MICHAEL D ALLEN

Group art unit

1642

Class/subclass

435/007.230

AIA (first inventor to file)

Yes

Entity status

Regular Undiscounted

Earliest publication #

US 2023-0266327 A1open_in_new

download

Earliest publication date

08/24/2023

MINNEAPOLIS, March 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, part of Bio-Techne's Molecular Diagnostics Division, has completed the Class C Certification under the new European Union In Vitro Diagnostic Regulation (IVDR) for its QuantideX® qPCR BCR-ABL IS Kit. Previously, the kit was CE-IVD marked for sale in the EU in compliance with the In Vitro Diagnostic Directive (IVDD), which has now been replaced by the IVDR.

The QuantideX qPCR BCR-ABL IS Kit gives labs a robust and reliable tool for monitoring chronic myeloid leukemia (CML) patients. The highly sensitive qPCR-based in vitro diagnostic test quantifies BCR-ABL1 and ABL1 transcripts in blood samples from patients with CML to determine their response to tyrosine kinase inhibitor (TKI) therapy. CML patients must undergo regular monitoring to ensure that they continue to receive the most appropriate treatment for their cancer. The QuantideX kit allows for direct reporting on the International Scale and further streamlines the workflow with easy-to-use analysis software. Clinical lab scientists can run up to 49 samples per plate for a scalable solution.

"Bio-Techne is dedicated to quality and compliance, and we applaud this new IVDR for strengthening the safety and performance requirements for diagnostic products," said Matt McManus, President of Bio-Techne's Diagnostics & Genomics Segment. "We are proud to achieve this new certification and will continue to provide the molecular diagnostic and liquid biopsy solutions that deliver world-class performance, scalability, and reliable results for the laboratory scientists, physicians, and patients who count on us."

This is a bit more interesting for when production starts.

Gemfields is pleased to announce the results of an auction comprised of commercial quality rough emeralds held during the period 5 - 22 March 2024.

Highlights: March 2024 - Commercial Quality Emerald Auction

· Total auction revenues of USD 17.1 million

· 43 lots were offered for sale, of which 40 were sold (93%)

· Average price of USD 4.45 per carat

· The 47 auctions of Kagem gemstones held since July 2009 have generated USD 1,006 million in total revenues, reaching the USD 1 billion mark

That one word - “expected”

Looks like Placees want some fluffing to get out.

Why not not say nothing until the Processing and Sorting Plants are commissioned and production has commenced.

Thousands of lives could be saved from lung cancer if screening programmes for the disease were introduced in Scotland, Wales and Northern Ireland, according to new research from Cancer Research UK (CRUK). 

 

Lung cancer is the leading cause of cancer death across the four countries of the UK. So far, England is the country implementing the UK National Screening Committee’s recommendation to offer lung cancer screening to all those at the highest risk of the disease (people aged between 55 and 74 who either smoke or used to smoke). It plans to reach 40% of this group by March 2025 and 100% by March 2030.

 

The targeted lung checks being introduced in England aim to help diagnose lung cancers earlier when they are more treatable. 

 

The latest calculations suggest equivalent lung cancer screening programmes could diagnose around 4,000 more lung cancer patients in Scotland at an early stage (stage 1 or 2) over the next decade, as well as 2,400 more people in Wales and 1,400 in Northern Ireland.

 

We strongly advocate early lung cancer screening initiatives, and we are developing a simple blood test for a biomarker called CIZ1B that is found in early-stage lung cancer patients. With more early-stage cancer detection methods available, more lives can be saved.

They need to get a shift on and join the fight.

CIZ need to get a shift on

Blood test reveals best lung cancer treatment https://www.bbc.co.uk/news/health-68624334

Or a sell order being worked.

From the same people who brought you the COVID vaccine. What could possibly go wrong. Based on tech from AZN covid vaccine.

Hi Bron.

It’s the wording I liked

“ with exciting technology ”

Starting to get interesting. If buying keeps up it could get back above 3p going into April.

But I think there’s a good chance of a sell off. Drawdown still in back of the mind. Hope it’s not just a Hopium pump to get the drawdown done and flipped.

Bear in mind a lot of buyers came in between 3p and 4.5p so they might look for an exit when they breakeven.

Just thoughts.

Be interested in Widglides view ? Bring the mood down

Re - cancers. From the pending patent application

0167) As used herein, the term "cancer" or "cancerous" refers to cells having the capacity for autonomous growth, i.e., an abnormal state or condition characterized by rapidly proliferating cell growth. The term is meant to include all types of cancerous growths or oncogenic processes, meta- static tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. The term "cancer" includes malignancies of

the various organ systems, such as those affecting, for example, lung, breast, thyroid, lymphoid, gastrointestinal, reproductive and genito-urinary tract, as well as adenocar- cinomas which include malignancies such as most colon cancers, renal-cell carcinoma, prostate cancer and/or testicu- lar tumours, non-small cell carcinoma of the lung, cancer of the small intestine and cancer of the esophagus.

(0168] Suitably, the cancer may be lung cancer, lym- phoma, kidney cancer, breast cancer, liver cancer, bladder cancer, ovarian or thyroid cancer.

[0169] In one embodiment, the cancer is lung cancer. The Lung cancer may be small cell lung cancer. The lung cancer may be non-small cell lung cancer.

Fast food from the RNS

This agreement represents a significant opportunity to bring early and cost-effective cancer detection to the people of China. It is estimated that about 95.8 million people in China have a high risk of lung cancer and if screening was performed every three years, then more than 30 million tests per year would be required. At a target price of about GBP100 per test, the total available market for tests based on the CIZ1B biomarker would be GBP3 billion. (Frost & Sullivan estimates the market size in China is US$5.7 billion).

Fast food

Look at Breast cancer.

Green price in China was £100 per test so lucky to get $150 - $250 per test in US. Can’t see $1000 price point

Just a reminder regarding warrant strike prices

On 14 May 2021 the Company issued investor warrants to subscribe for 11,000,000 Ordinary Shares at a fixed price of 15p per share valid for three years until 13 May 2024.

On 14 May 2021 the Company issued broker and adviser warrants to subscribe for 1,350,000 Ordinary Shares at a fixed price of 10p per share valid for three years until 13 May 2024. 250,000 of these broker warrants are automatically exercisable upon the Company's share price equalling 20p per share. The fair value of these warrants at 31 December 2021 was GBP36,000 and has been accounted for as a cost to the Company and a reduction of the share premium account ( see statement of changes in equity on pages 42 to 43).

Someone trying to prop this up with 10,000 trades while bigger sells get through.

Will it hold or back down into close and tomorrow with MM’s locking in new pi ‘ s